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Abstract
Background:  Intrahepatic cholangiocarcinomas are malignant tumors arising from the
intrahepatic biliary tract. The pathogenesis of these tumors remains unknown. Although there is a
marked global variation in prevalence, some recent studies have suggested an increase in mortality
from intrahepatic cholangiocarcinoma in several regions of low endemicity. As the study of
mortality trends may yield clues to possible etiological factors, we analyzed worldwide time trends
in mortality from biliary tract malignancies.
Methods: Annual age-standardized rates for individual countries were compiled for deaths from
biliary tract malignancies using the WHO database. These data were used to analyze gender and
site-specific trends in mortality rates.
Results: An increasing trend for mortality from intrahepatic cholangiocarcinoma was noted in
most countries. The average estimated annual percentage change (EAPC) in mortality rates for
males was 6.9 ± 1.5, and for females was 5.1 ± 1.0. Increased mortality rates were observed in all
geographic regions. Within Europe, increases were higher in Western Europe than in Central or
Northern Europe. In contrast, mortality rates for extrahepatic biliary tract malignancies showed a
decreasing trend in most countries, with an overall average EAPC of -0.3 ± 0.4 for males, but -1.3
± 0.4 for females.
Conclusions: There has been a marked global increase in mortality from intrahepatic, but not
extra-hepatic, biliary tract malignancies.
Background
Biliary tract tumors have proven challenging to treat and
manage due to their poor sensitivity to conventional ther-
apies and our inability to prevent or to detect early tumor
formation [1]. Furthermore, their etiology remains poorly
understood. Within the biliary tract, tumors can arise
from intrahepatic bile ducts (intrahepatic cholangiocarci-
noma), extrahepatic bile ducts, or the gall bladder. Intra-
hepatic cholangiocarcinomas are highly prevalent in
certain regions such as Thailand and Southeast Asia [2].
Because parasitic biliary tract infection is also endemic to
these regions, liver fluke infection and chronic biliary tract
inflammation have been identified as a strong risk factor
for cholangiocarcinoma [3,4]. Nevertheless the precise eti-
ology and pathogenesis of these tumors remain obscure
[5].
We have recently reported an increase in intrahepatic, but
not extrahepatic biliary tract tumors in the U.S [6]. An in-
crease in intrahepatic cholangiocarcinoma has also been
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reported in some other countries [7–9]. There have been
few studies of the epidemiology of these tumors, and the
abrupt increases in mortality related to cholangiocarcino-
ma have not previously been recognized, partly due to the
tendency to combine these tumors with hepatocellular
carcinoma as primary liver tumors in compiled reports
from cancer registries. As the analysis of time trends in
cancer mortality may provide clues to potential etiological
factors, we analyzed global trends in cancer mortality
from biliary tract malignancies over the past 1–3 decades
using data from the World Health Organization (WHO)
cancer database. Our aims were to assess the geographical
variations, gender differences and trends over time in site-
specific (intrahepatic versus extrahepatic) mortality from
biliary tract cancers.
Methods
Primary data sources
The WHO database was used to determine the deaths
from and mortality rates from biliary tract cancers [10].
Data was obtained for intrahepatic cholangiocarcinoma,
and for extrahepatic cholangiocarcinoma and gall blad-
der. Annual crude rates and age-standardized rates (1970
world population) by gender were obtained for all coun-
tries for which data was available for at least 5 consecutive
years.
Data analysis
To summarize the results, we have calculated the estimat-
ed annual percentage change (EAPC) over the interval for
which data were available by fitting a linear regression
equation to the natural logarithm of the annual age-stand-
ardized rates (ASR) using the calendar year as the inde-
pendent regressor variable. The statistical significance of
the regression coefficients (slopes) were then tested in the
usual manner and the EAPC was then calculated from the
slope of the resulting regression equation using the equa-
tion EAPC = 100 (eslope - 1) [11]. The gender and site-spe-
cific EAPC was derived separately for each country. To
assess geographical differences, data from individual
countries were grouped into continental regions. For Eu-
ropean countries, data were also grouped into broad geo-
graphic regions: Western Europe, Northern Europe and
Central Europe.
Results
Is mortality from intrahepatic cholangiocarcinoma in-
creasing worldwide?
To ascertain the rate of change of mortality from intrahe-
patic cholangiocarcinoma, we assessed trends in mortality
in reported data available in the WHO databank. Data
were available for twenty-two countries. Of these, two
countries each were from North America and Oceania,
three from Asia and the Middle East, and fifteen from Eu-
rope. Thus, all major geographic regions other than Africa
were represented. The EAPC in mortality from intrahepat-
ic cholangiocarcinoma was noted to be increasing in all
except three countries (Table 1). Of note, data were only
available for 8 or less years for each of the three countries
for which a decrease in mortality was reported.
An overall increase in mortality was observed in all re-
gions, with the greatest increases in the Americas, Oceania
and Western Europe (Figure 1). The increase in EAPC in
these regions was similar to that which we have recently
reported in the United States [6]. However, regional dif-
ferences were noticed in Europe, with lower reported in-
creases in EAPC in Central and Northern Europe. The
EAPC was lower for Asia/Middle East, although data from
regions of known high incidence of intrahepatic cholangi-
ocarcinoma such as Thailand and other southeastern na-
tions were not included in this analysis. Thus, there has
been a global increase in mortality related to intrahepatic
cholangiocarcinoma in regions of low disease prevalence.
Are there gender differences in the mortality from intrahe-
patic cholangiocarcinoma?
In order to ascertain whether there were gender differenc-
es in mortality from intrahepatic cholangiocarcinoma, we
analyzed the available gender-specific mortality rates for
both females and males in all countries and regions for
which data was available. For thirteen of the nineteen
countries, in which there was an overall increase in report-
ed mortality rates, the increase in mortality rates for males
was greater than for females. In those countries in which
rates were decreased, the decrease for males was the same
or more than that for females. Overall, the EAPC (mean ±
standard error) for males was 6.9 ± 1.5, and for females
was 5.1 ± 1.0. The trend towards a greater increase in mor-
tality from intrahepatic cholangiocarcinoma for males
was also noted in the United States [6].
Are there anatomic site-specific differences in mortality 
from biliary tract malignancies?
Intrahepatic tumors are clinically distinct from extrahe-
patic tumors. Indeed, the epidemiology and clinical be-
havior may vary with the anatomic location because of
differences in the biological characteristics of the underly-
ing biliary epithelia. We thus assessed trends in mortality
from malignancies of the extrahepatic biliary tract and
gallbladder. In contrast to the observations in intrahepatic
cholangiocarcinoma, the EAPC in mortality for extrahe-
patic biliary tract cancers decreased in most countries for
both males and females. The overall EAPC was -0.3 ± 0.4
for males, but -1.3 ± 0.4 for females. An increase in EAPC
for males was observed in 11 countries, but only in 6
countries for females. Overall, the reduction in mortality
from extrahepatic biliary tract malignancies was greater in
females than for males for all countries with decreased
mortality rates, with the exception of the United King-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/10
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dom. Thus, there has been a worldwide trend towards de-
creased mortality from extrahepatic tumors, particularly
for females.
Discussion
Our analysis indicates a global increase worldwide in
mortality related to intrahepatic biliary tract malignancies
over the past few decades. An increase is apparent in both
industrialized nations as well as developing nations. The
increase in mortality rates involves both males and fe-
males, although the trends indicate that the increase in
mortality is greater in males than in females.
The precise reasons for this increase remain unknown. Ap-
parent increases may arise from a variety of potential caus-
es, such as diagnostic misclassification, improved coding,
and enhanced diagnosis due to improved imaging studies
or more comprehensive evaluations. Any or all of these
may cause apparent increases in cancer mortality rates. In-
deed, diagnostic transfer from tumors that may have been
previously classified as extrahepatic and are now classified
as intrahepatic remains a possibility for some hilar tu-
mors. However, the global trends argue against any of
these as they may be expected to demonstrate regional
variations. Furthermore, differences in coding or classifi-
cation would be expected to affect all genders, and thus
would be unlikely to result in the observed gender differ-
Table 1: Trends in mortality from intrahepatic and extrahepatic biliary tract cancers, WHO Databank (EAPC = estimated annual per-
cent change in age-adjusted mortality rates)
Extrahepatic tumors Intrahepatic tumors
Region Country EAPC EAPC
Years Male Female Years Male Female
Americas Canada 1970–1997 -1.9 -2.8 1979–1997 7.9 8.8
USA 1970–1996 -2.5 -2.8 1979–1997 7.3 8.5
Oceania Australia 1970–1995 -1.9 -1.9 1979–1995 12.3 12.0
New Zealand 1970–1996 -2.7 -3.1 1979–1996 4.4 3.4
Western 
Europe
Austria 1970–1998 -1.5 -2.7 1980–1998 6.0 5.2
Belgium 1970–1994 -1.5 -2.5
Former FDR 1970–1990 -0.9 -1.8
France 1970–1996 1.2 -0.1 1983–1996 10.0 5.2
Germany 1990–1997 -1.2 -3.2 1991–1997 13.2 2.5
Greece 1970–1997 3.2 2.2 1979–1997 1.8 2.4
Ireland 1970–1996 -0.5 -2.5 1979–1996 10.9 8.5
Italy 1970–1995 2.9 2.3 1986–1995 4.2 5.9
Netherlands 1970–1995 -2.3 -3.9 1979–1995 3.5 0.2
Portugal 1984–1998 1.7 -0.1 1984–1996 10.4 10.3
Spain 1970–1994 2.9 3.0 1982–1995 18.3 12.7
UK 1970–1996 -3.7 -3.1 1979–1997 8.8 9.6
Central 
Europe
Czech 1986–1993 0.3 -2.2 1986–1993 -8.5 -5.6
Former Czech 1970–1991 1.4 0.6
Former GDR 1976–1990 -0.5 -1.9
Hungary 1970–1995 1.1 -0.6 1979–1995 1.5 2.1
Slovenia 1985–1996 -1.3 -2.5 1988–1996 22.1 10.3
Northern 
Europe
Iceland 1971–1995 -2.1 -2.3
Norway 1970–1995 0.1 -0.9 1989–1995 -3.0 -2.5
Sweden 1970–1995 0.6 -0.5 1987–1996 9.1 3.5
Asia / 
Middle 
East
Israel 1970–1991 -3.9 -4.4 1987–1996 -3.1 2.9
Japan 1970–1994 3.2 2.4 1979–1994 7.4 0.9
Singapore 1970–1996 1.7 1.0 1979–1998 6.1 6.0BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/10
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ences. Similarly, the increasing trends in regions of low
economic development suggest that better or improved
medical imaging and diagnostic technologies are unlikely
to have resulted in these global trends. Indeed, the diag-
nostic approach and classification has not changed over
the past several years. Although newer imaging and diag-
nostic modalities such as magnetic resonance cholangiog-
raphy or positron-emission tomography scanning may
Figure 1
Regional differences in the mean estimated annual percent change in age-adjusted (1970 World Standard population) gender-
specific mortality rates from intrahepatic biliary tract tumors (top) and gall-bladder and extra-hepatic biliary tract tumors (bot-
tom).
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enhance diagnosis of these tumors, their availability is
limited to only selected centers in a few countries.
Chronic biliary tract inflammation represents a major risk
factor for the development of cholangiocarcinoma. The
association between chronic parasitic infection of the bil-
iary tract and cholangiocarcinoma is obvious in regions of
high endemicity, such as in certain Far Eastern nations. In
Western nations, primary sclerosing cholangitis is a more
common risk factor identified with the development of
cholangiocarcinoma [12]. However, clinical observations
have not indicated an increase in the incidence of either
primary sclerosing cholangitis or biliary tract infections.
Thus, if the increase in mortality from cholangiocarcino-
ma is real, other potential etiological factors need to be
considered. Potential factors may include infections, tox-
ins or environmental agents causing biliary tract inflam-
mation, or malignant transformation. Recent reports
indicate a possible association between chronic hepatitis
C virus (HCV) infection and intrahepatic cholangiocarci-
noma [13]. However, this remains to be proven. Studies
correlating the geographical variations in incidence of
chronic HCV infection and mortality from cholangiocar-
cinoma should be considered. Although the hepatitis C vi-
rus infects biliary tract epithelium, it remains unknown
whether chronic viral infection predisposes to malignan-
cy.
The intrahepatic biliary epithelia varies from the extrahe-
patic biliary tract epithelia in its structure, function and
embryological derivation. Thus, the risk factors and
pathogenesis of tumors from different sites in the biliary
tract are likely to be distinct. Differences in the underlying
pathogenesis, as well as in their clinical presentation, may
thereby account for the divergent trends observed for int-
rahepatic and extrahepatic biliary tract tumors. Although
separate data on gall-bladder tumors compared to other
extrahepatic tumors was not available, these would also
be expected to exhibit different epidemiological and clin-
ical characteristics [14]. For example, an increase in the
numbers of cholecystectomies performed for non-malig-
nant gall-bladder disease may account for a decreased
mortality from gall-bladder tumors, but not other extrahe-
patic tumors.
In conclusion, there has been a marked global increase in
mortality from intrahepatic, but not extra-hepatic, biliary
tract malignancies. Furthermore, similar gender and site-
specific changes in time-trends of mortality from biliary
tract malignancies are present in most regions. The poor
response of intrahepatic cholangiocarcinoma to conven-
tional therapies, along with the concerning global in-
crease in mortality highlights the need for increased
efforts to understand their etiology and pathogenesis, as
well as further epidemiological investigation to identify
the reasons for these concerning trends.
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